UK: Lifesciences Snapshot: Summer 2008

Bringing you quarterly news of key developments of relevance to the Lifesciences sector.


London Agreement entered into force on 1 May

Following the deposit by France of the instrument of ratification with the German Ministry of Justice on 29 January, the London Agreement entered into force on 1 May 2008. The London Agreement is an amendment to the European Patent Convention that simplifies the language regime, largely or entirely waiving the need for translations of granted European patents. Countries such as the United Kingdom, France or Germany whose national language is also an official EPO language will dispense with translation requirements altogether. It is hoped that the reduction in costs will encourage small and medium-sized enterprises to pursue patent protection.

Actavis UK Limited -v- Merck & Co Inc [2008] EWCA Civ 444

The Court of Appeal has ruled that a Swiss form claim for the use of a pharmaceutical in the manufacture of a medicament could be allowed even where the novelty lay only in a new dosing regime. Emphasising the importance of taking an approach consistent with that of the EPO, the Court rejected arguments that it was bound not to allow such a claim on the basis of the Court of Appeal judgment in Bristol-Myers Squibb v Baker Norton.

The case is likely to be of great interest to the pharmaceutical industry, as it provides a more consistent approach to patentability of Swiss claims across the European Patent Convention countries, and will improve the prospects of pharmaceutical companies seeking to obtain patent protection in the UK for new applications of known substances.

For our full Law-Now on this decision, click here.

T 1319/04 - 3.3.02 Dosage regimen/KOS LIFE SCIENCES, INC. (EPO Board of Appeal)

The European Patent Office Board of Appeal has referred two questions concerning the interpretation of the "second medical use" provisions of the EPC 2000 as introduced in December last year. Specifically, whether it was possible to patent a medicament which is already known for treatment of the same illness where the only novel aspect is the new method of treatment / dosing.

For the full text of the decision, click here.

Government response to the EC's consultation on counterfeit medicines for human use

In March 2008, the European Commission released a public consultation on proposals for tackling counterfeit medicines. The Commission were of the opinion that the rise in counterfeit medicines has been caused by uncertainty as to the subjects of pharmaceutical legislation and guidance, shortcomings in product integrity and lack of compliance with pharmaceutical legislation and guidance. For a full copy of the public consultation, click here.

The UK government response to the European Commission's consultation on counterfeit medicines for human use was published in May 2008. In general, the UK government supported the Commission's proposals, although it asked for further information on how the proposed schemes would operate in practice. The government commented that the requirements of a unique packaging seal from the manufacturer and a ban on repackaging could prevent importers from complying with leaflet and labelling provisions. The government also expressed concern that proposals, in particular the proposal for a centrally accessible record system, could place too heavy a burden on the healthcare profession, especially if the adopted system is incompatible with national systems. For the government's full response, click here.


Regulation of NHS Advertisements

A Code of Practice for the Promotion of NHS-Funded Services has been issued to regulate the advertising of NHS-funded services. The new Code requires all providers of NHS-funded services to comply with applicable Advertising Standards Authority Codes and additional NHS-specific rules. The purpose is to ensure that patients have accurate information so that they can make effective choices and receive treatment that best fits their individual needs.

The Code applies to all providers of NHS-commissioned services whether independent sector, NHS providers or charities. It also applies to the entire range of promotional activity undertaken by providers of NHS-funded services, including advertising, direct marketing to patients and information directed at referring clinicians. In addition, it is intended to regulate the level of expenditure on promotional activity by requiring open disclosure of this by providers.

Enforcement of the Code will be split. Marketing communications already covered by the Advertising Codes will remain under the existing ASA regime. Complaints under the NHS-specific rules will be administered by the relevant commissioning Primary Care Trust and/or the Strategic Health Authority.

The Code sets out general principles and contains specific rules covering NHS brand/reputation protection; direct marketing to public and referring clinicians; claim substantiation and comparative claims; service providers' representatives; promotional expenditure; gifts and inducements to clinicians and commissioners as well as the public; testimonials and endorsements; sponsorship; compliance with undertakings and complaints and enforcement.

For the full Law-Now article on this click here.

Stock management of pharmaceuticals

Advocate General Ruiz-Jarabo's opinion in a case involving GlaxoSmithKline's (GSK) stock management policy of certain drugs in Greece was released on 1 April 2008. GSK's policy limited quantities of products sold to wholesalers to levels sufficient to meet the needs of the Greek market. GSK was clear that the policy was intended to limit the levels of parallel trade from Greece. Wholesalers claimed that this policy was an abuse of dominant position under Article 82 EC Treaty. Taking a tough stance towards GSK and the pharmaceutical innovator in general, AG Ruiz-Jarabo considers that a restriction of supply by a dominant pharmaceutical company in order to limit parallel trade can in principle be a breach of Article 82 EC Treaty. He does not accept that the restriction may be justified due to the negative impact of parallel trade on GSK's incentives to innovate. It remains to be seen whether the ECJ will follow this opinion.

For the full Law-Now article on this click here.


New UK law of fair dealing

Two sets of UK Regulations came into force on 26 May 2008, implementing the EC Unfair Commercial Practices Directive (2005/29/EC). These are the Consumer Protection from Unfair Trading Regulations 2008 (SI 2008/1277 – "CPRs") and the Business Protection from Misleading Marketing Regulations 2008 (SI 2008/1276 – "BPRs").

Under the CPRs, unfair commercial practices are prohibited. A practice is unfair if it is a misleading action, a misleading omission, an aggressive commercial practice or is a practice listed in schedule 1 of the CPRs.

The BPRs regulate unfair business-to-business practices in the UK. The Regulations do not alter businesses' obligations not to use advertisements that mislead other businesses. The main change from the previous legislation is that the rules apply to "indications" and not merely traditional advertising.

For the full Law-Now article on this click here.

This article was written for Law-Now, CMS Cameron McKenna's free online information service. To register for Law-Now, please go to

Law-Now information is for general purposes and guidance only. The information and opinions expressed in all Law-Now articles are not necessarily comprehensive and do not purport to give professional or legal advice. All Law-Now information relates to circumstances prevailing at the date of its original publication and may not have been updated to reflect subsequent developments.

The original publication date for this article was 29/07/2008.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.